PFE vs RTX: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and RTX Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
VS
RTX Corporation · Industrials
$193.54
+33.0% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
RTX has more upside to fair value
(+33.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
RTX |
| Current Price |
$27.64 |
$193.54 |
| Fair Value Estimate |
$30.94 |
$257.36 |
| Upside to Fair Value |
+12.0%
|
+33.0%
|
| Market Cap |
$157.5B |
$260.9B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
17.4x
|
18.1x
|
| Price / Sales |
2.5x
|
2.8x
|
| Price / FCF |
14.3x
|
21.7x
|
| Revenue Growth YoY |
+2.6%
|
+14.5%
|
| Gross Margin |
71.3%
|
20.3%
|
| Operating Margin |
25.1%
|
11.2%
|
| Return on Equity |
4.9%
|
11.8%
|
| Dividend Yield |
6.22% |
1.46% |
| FCF Yield |
6.97%
|
4.6%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
RTX Corporation is a $260.85 billion aerospace and defense conglomerate operating three segments — Collins Aerospace, Pratt & Whitney, and Raytheon — serving commercial aviation, military, and government customers worldwide with 180,000 employees. The business quality is high: it holds intangible-asset and switching-cost advantages rooted in long-cycle engine programs, proprietary defense electro…
Accumulation Zones
| Metric |
PFE |
RTX |
| Zone Low |
$23.21 |
$193.02 |
| Zone High |
$26.30 |
$218.76 |
| In Buy Zone? |
No
|
Yes
|